

# 'Playing a global role is only possible through production'

Deva Holding Chairman of the Executive Board and CEO Philipp Haas stated that “we planned the investments in 2013 based on the fact that, in Turkey, pharmaceutical import is more than 10 times higher the pharmaceutical export”. Indicating that pharmaceutical import increased almost by seven times between the years of 2000 and 2012, Mr. Haas expressed that “Turkey ranks the 16th on the world in respect of market size of pharmaceutical sector”

Mr. Haas said that “We believe that Turkey can be a global actor in pharmaceutical industry only through domestic manufacture of majority of products imported today. This is our dream for the following years. As DEVA Holding, we hold our end of the bargain to lead this movement”. DEVA Holding declared a turnover of 419.5 million TL and a net profit of 34.2 million TL. Mr. Haas stated that year of 2012 was realized in line with their expectations. ■ **ECONOMY SERVICE**